Skip to content

Study · Not a test of the peptide alone · 2024

4 results

Long-Term Effects of Incretin-Based Drugs on Glycemic Control in Permanent Neonatal Diabetes.

Oshiro A, Aotani R, Sakamoto W, Kitazono T, Ohkuma T

JCEM case reports18 Oct 2024Cited by 1 (Europe PMC)

PMID39430732 (opens in a new tab)PMCIDPMC11487289 (opens in a new tab)DOI10.1210/jcemcr/luae188 (opens in a new tab)PepBankPUB-39430732
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Permanent neonatal diabetes mellitus (PNDM) is a genetic disorder, characterized by a decrease in endogenous insulin secretion. Therefore, exogenous insulin supplementation plays a central role in controlling glycemia. Although adding a sulfonylurea can help to discontinue insulin, discontinuation is sometimes difficult when the sulfonylurea is administered at older ages. A 24-year-old woman with longstanding PNDM who had poor glycemic control using insulin (47 U/day) and high-dose glibenclamide (0.6 mg/kg/day), had successfully discontinued insulin after initiating the dipeptidyl peptidase-4 inhibitor sitagliptin (50 mg/day). Additionally, hemoglobin A1c levels decreased by 4.8%. Double dosing of sitagliptin and subsequent switching to the glucagon-like peptide-1 receptor agonist semaglutide (0.25 mg/week followed by 0.5 mg/week) further decreased hemoglobin A1c values, with graded improvements in endogenous insulin secretion. There were no episodes of hypoglycemia during which glibenclamide was titrated down from 0.6 to 0.4 mg/kg/day. Intra- and inter-day glucose variability as assessed by continuous glucose monitoring was also improved. In patients with PNDM, administration and dose escalation of incretin-based drugs, in addition to a high-dose sulfonylurea, could be a useful treatment strategy. This strategy may be helpful for discontinuing insulin, downtitrating sulfonylureas, and subsequent achievement of better glycemic control regarding long-term stability and short-term variability.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a woman with permanent neonatal diabetes, a sequence of double-dose sitagliptin then semaglutide on top of glibenclamide further decreased HbA1c.

    In plain wordsIn one woman with permanent neonatal diabetes, a drug sequence that ended with semaglutide lowered HbA1c further.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c after switch to semaglutide
    Study

    n = 1

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    Double dosing of sitagliptin and subsequent switching to the glucagon-like peptide-1 receptor agonist semaglutide (0.25 mg/week followed by 0.5 mg/week) further decreased hemoglobin A1c values, with graded improvements in endogenous insulin secretion.
    1 context sentence
    Summary · context
    A 24-year-old woman with longstanding PNDM who had poor glycemic control using insulin (47 U/day) and high-dose glibenclamide (0.6 mg/kg/day), had successfully discontinued insulin after initiating the dipeptidyl peptidase-4 inhibitor sitagliptin (50 mg/day).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a woman with permanent neonatal diabetes, the sitagliptin then semaglutide sequence came with graded improvements in endogenous insulin secretion.

    In plain wordsIn one woman with permanent neonatal diabetes, her own insulin release improved step by step during a drug sequence that included semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseEndogenous insulin secretion
    Study

    n = 1

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    with graded improvements in endogenous insulin secretion.
    2 context sentences
    Summary · context
    Double dosing of sitagliptin and subsequent switching to the glucagon-like peptide-1 receptor agonist semaglutide (0.25 mg/week followed by 0.5 mg/week) further decreased hemoglobin A1c values, with graded improvements in endogenous insulin secretion.
    Summary · context
    A 24-year-old woman with longstanding PNDM who had poor glycemic control using insulin (47 U/day) and high-dose glibenclamide (0.6 mg/kg/day), had successfully discontinued insulin after initiating the dipeptidyl peptidase-4 inhibitor sitagliptin (50 mg/day).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In the woman, no hypoglycemia episodes occurred while glibenclamide was titrated down from 0.6 to 0.4 mg/kg/day.

    In plain wordsIn one woman with permanent neonatal diabetes, no low blood sugar episodes occurred while her sulfonylurea dose was lowered.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypoglycemia episodes
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones

    Source sentences

    Summary
    There were no episodes of hypoglycemia during which glibenclamide was titrated down from 0.6 to 0.4 mg/kg/day.
    1 context sentence
    Summary · context
    A 24-year-old woman with longstanding PNDM who had poor glycemic control using insulin (47 U/day) and high-dose glibenclamide (0.6 mg/kg/day), had successfully discontinued insulin after initiating the dipeptidyl peptidase-4 inhibitor sitagliptin (50 mg/day).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In the woman, intra- and inter-day glucose variability on continuous glucose monitoring was improved.

    In plain wordsIn one woman with permanent neonatal diabetes, day-to-day blood sugar swings improved during the incretin drug treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlucose variability by continuous glucose monitoring
    Study

    n = 1

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    Intra- and inter-day glucose variability as assessed by continuous glucose monitoring was also improved.
    1 context sentence
    Summary · context
    A 24-year-old woman with longstanding PNDM who had poor glycemic control using insulin (47 U/day) and high-dose glibenclamide (0.6 mg/kg/day), had successfully discontinued insulin after initiating the dipeptidyl peptidase-4 inhibitor sitagliptin (50 mg/day).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.